<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501939</url>
  </required_header>
  <id_info>
    <org_study_id>191407</org_study_id>
    <nct_id>NCT04501939</nct_id>
  </id_info>
  <brief_title>Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax</brief_title>
  <acronym>Venetoclax</acronym>
  <official_title>Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncternal Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab&#xD;
      consolidation in patients with measurable disease on venetoclax.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 study to test whether cirmtuzumab in combination with venetoclax given as&#xD;
      consolidation therapy can decrease the number of cancer cells that may be left in the bone&#xD;
      marrow or in the blood in patients who have been treated with venetoclax for at least one&#xD;
      year. Consolidation therapy is given after initial cancer treatment to further reduce the&#xD;
      number of cancer cells that may be left in the body. Cirmtuzumab, a monoclonal antibody that&#xD;
      inhibits receptor tyrosine kinase like orphan receptor (ROR1) signaling and stemness, may be&#xD;
      effective in reducing the risk of disease progression in patients with detectable minimal&#xD;
      residual disease (MRD) after treatment with venetoclax.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2020</start_date>
  <completion_date type="Anticipated">July 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 22, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with undetectable measurable residual disease after 6 months of cirmtuzumab + venetoclax treatment.</measure>
    <time_frame>6-24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.</measure>
    <time_frame>9-15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next CLL treatment.</measure>
    <time_frame>9-24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in gene expression in leukemic cells</measure>
    <time_frame>9-15 months</time_frame>
    <description>The change in gene expression of leukemia cells by single cell PCR or RNA after treatment with cirmtuzumab, including analysis of archival pre-venetoclax sample, when available.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Cirmtuzumab + Venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive a minimum of 6 cycles (cycle = 28 days) of therapy with venetoclax and cirmtuzumab during the treatment period. For patients who achieve undetectable minimal residual disease (uMRD) positive after cycle 6, an additional 6 cycles of venetoclax and cirmtuzumab may be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cirmtuzumab</intervention_name>
    <description>Cycle 1, Day 1 &amp; 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg</description>
    <arm_group_label>Cirmtuzumab + Venetoclax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.</description>
    <arm_group_label>Cirmtuzumab + Venetoclax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have detectable CLL/SLL (&gt; 0.01% leukemia cells present)&#xD;
&#xD;
          -  Must have received at least 12 months of venetoclax.&#xD;
&#xD;
          -  Patients may be receiving venetoclax at the time of screening and study entry.&#xD;
&#xD;
          -  Patients who have discontinued venetoclax more than 6 months prior to study entry must&#xD;
             still have a disease burden meeting criteria for low risk of TLS (i.e. no lymph node&#xD;
             greater than 5 cm in diameter; absolute lymphocyte count less than 25 k/uL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Evidence of other clinically significant uncontrolled condition(s) including, but not&#xD;
        limited to:&#xD;
&#xD;
          -  Uncontrolled and/or active systemic infection (viral, bacterial or fungal)&#xD;
&#xD;
          -  Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note:&#xD;
             subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface&#xD;
             (HBs) antigen negative, anti-HBs antibody positive and anti-hepatitis B core (HBc)&#xD;
             antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins&#xD;
             (IVIG) may participate.&#xD;
&#xD;
          -  Child class B or C cirrhosis&#xD;
&#xD;
        Treatment with any of the following within 7 days prior to the first dose of cirmtuzumab:&#xD;
&#xD;
          -  Steroid therapy for anti-neoplastic intent&#xD;
&#xD;
          -  Biologic agent (monoclonal antibody) within 30 days for anti-neoplastic intent.&#xD;
&#xD;
          -  Chemotherapy (purine analog or alkylating agent) or target small molecule agent within&#xD;
             14 days or 5 half-lives (whichever is shorter), or has not recovered to less than&#xD;
             CTCAE grade 2 clinically significant adverse effect(s)/toxicity(s) of previous&#xD;
             therapy.&#xD;
&#xD;
          -  CLL therapy, aside from venetoclax.&#xD;
&#xD;
          -  History of other malignancy that could affect compliance with the protocol or&#xD;
             interpretation of results (example: patients with a history of curatively treated&#xD;
             basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are&#xD;
             generally eligible.)&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin M Heyman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin M Heyman, MD</last_name>
    <phone>858-246-3038</phone>
    <email>bheyman@ucsd.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSD Koman Family Outpatient Pavilion</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Miller</last_name>
      <phone>858-249-3000</phone>
      <email>eamiller@ucsd.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Benjamin Heyman</investigator_full_name>
    <investigator_title>Asst Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>cirmtuzumab</keyword>
  <keyword>venetoclax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

